Navigation Links
Bionovo Announces Closing of Follow-on Offering of Common Stock and Warrants
Date:2/2/2011

Chinese medicine (TCM). Bionovo recognizes the opportunity to commercialize a product that would be as effective as hormone therapy, without the health risks. Menerba has completed a Phase 2 trial with positive results for efficacy and has been evaluated by an independent Data and Safety Monitoring Board and passed through a standard two-round examination for safety. Menerba also has been shown in animal studies to prevent the proliferation of breast cancer and to have a beneficial effect on osteoporosis, though this has not yet been studied in humans.

About Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The Company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property pr
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Bionovo, Inc. to Announce First Quarter Fiscal Year 2010 Financial Results on Tuesday, May 11, 2010
2. Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer
3. Bionovo to Present on Novel Female-Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society
4. Bionovo, Inc. to Announce Second Quarter Fiscal Year 2009 Financial Results on Monday, August 10, 2009
5. Bionovo Appoints Dr. Klaus Kohl as Chief Technical Officer
6. Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108
7. Bionovo Announces 2008 Highlights and Year-End Financial Results
8. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
9. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
10. Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform
11. Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Selexis SA, a serial ... Cell Banks (RCBs) used for drug discovery to commercial ... will include Next-Generation Sequencing (NGS) data packages. ... biologic manufacturing by ensuring the integrity of the gene, ...
(Date:1/22/2015)... , 22 de enero de 2015  El Dr. ... su llamada a nominaciones para 2015. Este prestigioso premio ... o tiene el potencial para hacer, contribuciones destacadas para ... aceptarán hasta el 15 de marzo de 2015 a ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... has been honored for its commitment to sustainability with inclusion ... Varian is the highest ranked healthcare equipment company among the ... during the World Economic Forum at Davos, Switzerland ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... The Board of,Directors of Shire plc (LSE: SHP, ... announces today that David Mott will,join the Board ... Mr Mott is Chief Executive Officer and ... to in 2000. He joined MedImmune in 1992 ...
... ... Data, VANCOUVER ... a clinical-stage developer of drugs for infectious,diseases will present at the Acumen ... York Palace Hotel in New York,NY on November 5-7, 2007. Jim DeMesa, ...
... Oct. 31 Amedica Corporation,an orthopedic implants company ... the U.S. Food and Drug Administration,has granted 510(k) ... The Valeo(TM) Cervical Plate system combines features aimed ... The,Valeo(TM) Cervical Plate system is intended for anterior ...
Cached Biology Technology:David Mott Appointed Non Executive Director at Shire 2David Mott Appointed Non Executive Director at Shire 3MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 3
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... technology and tech stocks, releases video from the CES 2015 ... security consultant Apollo Robbins . Apollo shows ... Wocket™ biometric smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... of the world, rice is one of the most important plants ... part, the task of a group of three researchers from Iowa ... are looking at two bacterial diseases of rice. The most costly ... called Xanthomonas oryzae pathovar oryzae , and can diminish yield ...
... is increasingly undervalued in conflicts over reproductive rights, including ... a new study by a University of Illinois legal ... recent reproductive rights cases shows that judges may shortchange ... interests, such as religious freedom, potentially leading to rulings ...
... by the dazzling displays of green light often seen ... at Scripps Institution of Oceanography at UC San Diego ... produce the green glow and the biological mechanisms behind ... attract suitors in an undersea mating ritual. Research conducted ...
Cached Biology News:Researchers examine bacterial rice diseases, search for genetic solutions 2Study: Health undervalued in reproductive rights debate 2Scripps scientists help decode mysterious green glow of the sea 2
... This volume provides excellent background information, ... study of major HIV proteins including: the ... integrase and protease. Expression of HIV proteins ... Rev assays; HIV/CD4 interactions; transient assays for ...
Human Glypican 2 Biotinylated Affinity Purified PAb...
Human Contactin-2/TAG1 Affinity Purified Polyclonal Ab...
Tachykinin (H-2)...
Biology Products: